Moleculin Biotech, Inc. MBRX 深 滬
等待開盤 06-25 09:30:00 美东时间
2.93
+0.180
+6.55%
華盛通- 最 高2.94
- 今 開2.61
- 成交量 91.50万股
- 最 低 2.61
- 昨 收 2.75
- 總市值 1563.55万
- 52周最高 24.00
- 市盈率 靜 --
- 換手率 17.15%
- 52周最低 1.79
- 委 比 -81.24%
- 總股本 533.64万
- 歷史最高 21555.00
- 量 比 0.37
- 振 幅 12.00%
- 歷史最低 1.79
- 每 手 1
- 風險率 5.10%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Moleculin market research shows oncologists likely to prescribe Annamycin in relapsed/refractory AML
Moleculin market research shows oncologists likely to prescribe Annamycin in relapsed/refractory AML Moleculin Biotech disclosed results from an independent market assessment on Annamycin in relapsed or refractory acute myeloid leukemia. Findings were presented now, not flagged for a future conferen
06-05 20:29
Moleculin Biotech Announces That New Data Further Reinforcing The Differentiated Cardiac Safety Profile Of Its Lead Drug Candidate, Annamycin, Was Presented At The American Society Of Clinical Oncology Annual Meeting
The poster presentation, titled "Cardiac safety of L-annamycin at high cumulative anthracycline exposure: Pooled analysis," highlighted findings from a pooled analysis across five completed clinical trials evaluating
05-29 20:26
Moleculin says pooled ASCO data show no detectable cardiotoxicity with Annamycin at high cumulative exposure
Moleculin says pooled ASCO data show no detectable cardiotoxicity with Annamycin at high cumulative exposure Moleculin Biotech presented ASCO 2026 data from a pooled analysis of five completed trials of Annamycin in AML or soft tissue sarcoma. The analysis found no detectable signs of drug-related h
05-29 20:21
Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
Moleculin Biotech's lead drug candidate, Annamycin, demonstrated a differentiated cardiac safety profile in a pooled analysis of five clinical trials, with no detectable cardiotoxicity even at high cumulative doses. The findings, presented at the 2026 ASCO Annual Meeting, were independently reviewed by Cleveland Clinic cardiologists. Annamycin showed no significant change in left ventricular ejection fraction (LVEF) and no correlation between dos...
05-29 12:21
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
Moleculin Biotech announced that its lead drug candidate, Annamycin, has been accepted for a poster presentation at the 2026 ASCO Annual Meeting. The presentation will focus on the cardiac safety of Annamycin, with data from five clinical trials showing no significant cardiotoxicity. Key findings include no change in left ventricular ejection fraction (LVEF) and no correlation between dose or age and LVEF changes. Walter Klemp, CEO, highlighted t...
05-21 21:02
Moleculin Biotech Q1 EPS $(3.54) Misses $(1.57) Estimate
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(3.54) per share which missed the analyst consensus estimate of $(1.57) by 125.48 percent. This is a 77.59 percent increase over losses of $(15.80) per share
05-15 21:20
Moleculin Biotech Announces Significant Advancement In IP Portfolio With Issuance Of Hong Kong Patent Covering Proprietary Method Of Reconstituting Liposomal Annamycin
Solid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data ReleaseHOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today
05-08 20:47
Moleculin Biotech secures Hong Kong patent for liposomal Annamycin reconstitution method
Moleculin Biotech secures Hong Kong patent for liposomal Annamycin reconstitution method Moleculin Biotech won a Hong Kong patent covering its method of reconstituting liposomal Annamycin, extending protection through June 25, 2040. Patent, No. 40073244, is jointly owned with University of Texas Sys
05-08 20:45
Moleculin Highlights Promising Preclinical Data for L-ANN
Moleculin Biotech ( ($MBRX) ) has shared an announcement. On April 23, 2026, Mo...
04-23 20:51
Moleculin to present annamycin cardiac safety pooled analysis at ASCO 2026
Moleculin to present annamycin cardiac safety pooled analysis at ASCO 2026 Moleculin Biotech disclosed acceptance of an abstract on its lead drug candidate annamycin for poster presentation at 2026 ASCO Annual Meeting. Data will be presented May 30, 2026, in Chicago. Poster reports pooled analysis i
04-21 20:36
